经导管主动脉瓣假体变形与低衰减瓣叶增厚及临床结局的关系
研究前瞻性纳入565例接受球囊扩张式SAPIEN3或自膨胀式EVOLUT TAVR的患者,于术后30天行心脏CT筛查低衰减瓣叶增厚(HALT)。结果显示HALT与假体框架变形、瓣叶不对称及新窦体积较小相关,且HALT与1年全因死亡、心源性死亡及死亡与心衰住院复合终点风险升高相关。
要点
- TAVR术后30天HALT见于21%的SAPIEN3患者和16%的EVOLUT患者。
- 假体框架变形、瓣叶不对称及新窦体积较小与HALT发生直接相关。
- HALT与1年全因死亡、心源性死亡及死亡与心衰住院复合终点风险升高相关。
核心结论
- TAVR假体非均匀扩张导致框架变形、瓣叶不对称及新窦体积较小,与TAVR患者HALT的发生相关。
- 这些数据可能对假体瓣膜设计和释放技术有启示,以改善患者临床结局。
研究设计与样本
- 前瞻性研究,纳入565例接受球囊扩张式SAPIEN3或自膨胀式EVOLUT TAVR的患者。
- 于术后30天行心脏CT筛查HALT,并在术后CT上分析假体变形、瓣叶不对称扩张、假体窦体积及交界对齐。
- 计算假体变形指数,>1.00表示相对中段扩张不足;采用时间-事件模型评估HALT与临床结局的关联。
主要发现
- TAVR术后30天HALT见于21%的SAPIEN3患者和16%的EVOLUT患者。
- HALT发生与更大的假体框架变形(P<0.001)、更差的瓣叶不对称(P<0.001)及更小的TAVR新窦体积(P<0.001)直接相关。
- 上述关系在两种假体类型及其所有尺寸范围内均存在(均P<0.05)。
- 在校正既往与HALT相关临床变量(如抗凝治疗)的多变量分析中,TAVR假体变形变量仍可预测HALT。
- HALT与假体血流动力学变化无关,但与1年死亡风险相关:全因死亡(HR 2.98,95%CI 1.57-5.63;P=0.001)、心源性死亡(HR 4.58,95%CI 1.81-11.6;P=0.001)及全因死亡与心衰住院复合终点(HR 1.94,95%CI 1.14-3.30;P=0.02),校正年龄、性别和合并症。
临床怎么用
- TAVR术后可通过CT评估假体框架变形、瓣叶不对称及新窦体积,识别HALT高风险患者。
- 对存在假体变形的患者应关注HALT及1年死亡风险,考虑优化瓣膜设计和释放技术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although transcatheter aortic valve replacement (TAVR) therapy continues to grow, there have been concerns about the occurrence of hypoattenuating leaflet thickening (HALT), which may affect prosthesis function or durability. This study aimed to examine prosthesis frame factors and correlate their extent to the frequency of HALT and clinical outcomes. METHODS: We prospectively examined 565 patients with cardiac computed tomography screening for HALT at 30 days after balloon-expandable SAPIEN3 and self-expanding EVOLUT TAVR. Deformation of the TAVR prostheses, asymmetric prosthesis leaflet expansion, prosthesis sinus volumes, and commissural alignment were analyzed on the postprocedural computed tomography. For descriptive purposes, an index of prosthesis deformation was calculated, with values >1.00 representing relative midsegment underexpansion. A time-to-event model was performed to evaluate the association of HALT with the clinical outcome. RESULTS: Overall, HALT was present in 21% of SAPIEN3 patients and in 16% of EVOLUT patients at 30 days after TAVR. The occurrence of HALT was directly associated with greater prosthesis frame deformation (P<0.001), worse asymmetry of the leaflets (P<0.001), and smaller TAVR neosinus volumes (P<0.001). These relations were present in both prosthetic types and in all of their size ranges (all P<0.05). In multivariable analyses that include clinical variables previously associated with HALT (eg, anticoagulant therapy), variables of TAVR prosthesis deformation remained predictive of HALT. Although HALT was not associated with changes in prosthetic hemodynamics, its presence was associated with the risk of mortality at 1 year, with respect to greater incidences of all-cause mortality (hazard ratio, 2.98 [95% CI, 1.57-5.63]; P=0.001), cardiac death (hazard ratio, 4.58 [95% CI, 1.81-11.6]; P=0.001), and a composite outcome of all-cause mortality and heart failure hospitalization (hazard ratio, 1.94 [95% CI, 1.14-3.30]; P=0.02) with adjustment for age, sex, and comorbidities. CONCLUSIONS: Nonuniform expansion of TAVR prostheses resulting in frame deformation, asymmetric leaflet, and smaller neosinus volume is related to occurrence of HALT in patients who undergo TAVR. These data may have implications for both prosthesis valve design and deployment techniques to improve clinical outcomes for these patients.
引用
- Fukui M, Bapat VN, Garcia S, et al. Deformation of Transcatheter Aortic Valve Prostheses: Implications for Hypoattenuating Leaflet Thickening and Clinical Outcomes. Circulation. 2022. PMID: 35862182. doi:10.1161/CIRCULATIONAHA.121.058339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。